Savara (SVRA) AI Stock Analysis

• Market Cap: $413.08M
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: N/A
• EPS Growth: -44.25%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 172,836,930
• 10 Day Avg. Volume: 1,608,523
• 30 Day Avg. Volume: 1,269,375
• PEG Ratio: 0.23
• Price to Book (P/B): 2.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.85
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 387.57
• Enterprise Value/Gross Profit: 3.15K
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $7.00
• Price Target Upside: 192.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 46 Neutral
• Price Target: ―

Savara's stock score reflects a company in the developmental stage, with significant financial risks due to its lack of revenue and ongoing cash burn. However, a strong balance sheet and recent financing developments provide some stability. Technical indicators suggest short-term positive momentum, but valuation remains challenging with a negative P/E ratio. The recent loan agreement is a positive step, potentially facilitating future growth and commercialization efforts.

Positive Factors

Financial Position

The company expects the current cash runway of $172.5M to last into 2H27, which comfortably surpasses US launch timing.

Market Potential

Molbreevi stands to become the first and only approved therapy in the aPAP space, indicating a unique market position.

Negative Factors

Management Confidence

Concerns arise because Savara management has not conveyed confidence that past mistakes will not be repeated, especially with ongoing dialogue with the FDA.

Regulatory Challenges

There is added uncertainty and execution concerns due to the Refusal to File letter from the FDA, which could affect the approval process.

Savara Business Overview & Revenue Model

Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Savara Inc. does not generate revenue from product sales. Instead, the company primarily relies on funding through equity offerings, grants, and strategic partnerships to finance its research and development activities. Significant partnerships with research institutions and pharmaceutical companies may also provide financial support and resources necessary for clinical trials and drug development. Once regulatory approval for its product candidates is obtained, Savara aims to monetize through product sales, licensing agreements, and potential collaborations for commercialization.

Savara Financial Statement Overview

Summary

Savara is in a typical developmental stage for a biotech company, with no revenue and consistent losses as it invests heavily in R&D. While the balance sheet is strong with substantial equity and cash reserves, the income statement and cash flow highlight the risks of ongoing cash burn and the need for continued external financing. Investors should be aware of the potential for future dilution and the importance of achieving revenue milestones to improve financial health.

Income Statement

Savara's income statement reveals a challenging financial position, with no revenue generation over the past years. Consistent negative EBIT and net income figures indicate ongoing losses, which is common in early-stage biotech firms focused on R&D. The lack of revenue growth and profitability reflects the company's current unprofitable operations.

Balance Sheet

The balance sheet shows a relatively strong equity position compared to liabilities, with a debt-to-equity ratio of 0.16 in 2024, suggesting low leverage. However, the company’s equity ratio of 80.5% indicates a strong reliance on equity financing, which is a positive sign for stability. The company's cash position is robust, providing a cushion for operations despite ongoing losses.

Cash Flow

The cash flow statement reflects negative free cash flow, indicating the company is burning through cash without generating enough income to cover its expenditures. However, significant financing inflows show the company's ability to secure funding, which is essential for sustaining operations. The absence of positive free cash flow growth underscores challenges in achieving operational cash flow sufficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	272.00K	0.00	0.00	0.00	0.00	257.00K
Gross Profit	67.00K	0.00	-44.26M	-167.00K	-367.00K	221.96K
EBITDA	-109.03M	-103.07M	-59.13M	-37.90M	-40.37M	-47.44M
Net Income	-102.17M	-95.88M	-54.70M	-38.95M	-45.30M	-51.10M
Balance Sheet
Total Assets	189.32M	212.88M	177.56M	139.78M	176.60M	97.75M
Cash, Cash Equivalents and Short-Term Investments	172.50M	196.33M	162.32M	125.88M	161.17M	82.19M
Total Debt	29.52M	26.73M	26.49M	26.14M	25.79M	25.28M
Total Liabilities	41.47M	41.43M	37.19M	32.00M	32.10M	33.36M
Stockholders Equity	147.85M	171.45M	140.37M	107.78M	144.50M	64.38M
Cash Flow
Free Cash Flow	-95.65M	-89.11M	-51.36M	-34.56M	-40.14M	-43.13M
Operating Cash Flow	-95.63M	-89.09M	-51.06M	-34.55M	-40.08M	-39.84M
Investing Cash Flow	-21.41M	-39.94M	-57.12M	52.65M	-69.46M	9.05M
Financing Cash Flow	119.85M	117.58M	82.78M	87.00K	120.81M	3.69K

Savara Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Neutral. The current price of 2.39 is above the 20-day moving average (MA) of 2.21, below the 50-day MA of 2.54, and below the 200-day MA of 3.01, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 71.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SVRA.

Savara Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	68 Neutral	$928.69M	65.43	33.47%	―	29.77%	―
BCYC	58 Neutral	$553.62M	―	-37.13%	―	-38.14%	29.69%
URGN	57 Neutral	$656.57M	―	-452.20%	―	8.98%	6.32%
ARVN	56 Neutral	$575.90M	―	-35.41%	―	―	―
Sector *	50 Neutral	AU$2.48B	3.20	-57.47%	2.71%	36.73%	13.67%
KURA	47 Neutral	$543.69M	―	-41.84%	―	―	3.95%
SVRA	46 Neutral	$413.08M	―	-75.77%	―	―	-44.25%

Savara Corporate Events

Savara Secures $200 Million Loan Agreement with Hercules

On March 26, 2025, Savara announced a loan agreement with Hercules Capital for up to $200 million, aimed at strengthening its financial position following the submission of a Biologics License Application to the FDA for MOLBREEVI, a potential first-in-class therapy for aPAP. The agreement includes an initial $30 million to refinance existing debt, with additional funds contingent on FDA approval and other milestones, supporting Savara’s efforts to commercialize MOLBREEVI in the U.S. and Europe.